StockData
Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc. (CRDL) stock

CRDLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 40-F on Mar 31, 2026Score 5/30
$0.86−0.02 (-2.28%)

Close on Nov 20, 2026Market cap $86.48MP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025

Valuation

Market cap
C$123.29M
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
-19.37%

Fundamentals

EPS, diluted
-0.39 CAD
Free cash flow
-C$23.88M

Trading

Previous close
$0.88
Open
$0.88
Day's range
$0.84 – $0.90
Volume
552,966
Average volume (20 days)
523,945
Beta (5 years)
1.19
RSI (14 days)
25.6
Volatility (1 year)
62.3%
Relative volume
0.46×
WACC
11.0%

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 20, 2026. The S&P 500 is measured by the SPY fund.

PeriodCRDLS&P 500DifferenceCRDL per yearS&P 500 per year
1 month-25.0%-10.3%−14.7 pts
3 months-54.2%-9.3%−44.9 pts
Year to date-9.6%+1.9%−11.5 pts
1 year-10.6%+6.9%−17.5 pts
3 years+0.2%+57.5%−57.3 pts+0.1%+16.3%
5 years-57.9%+57.3%−115.2 pts-15.9%+9.5%

Seven years at a glance

Fiscal years 2019 to 2025, CAD

Revenue

–

Operating income

-C$34.32M

EPS, diluted

-0.39 CAD

Free cash flow

-C$23.88M
Reported period

Press releases

Releases Cardiol Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Cardiol Therapeutics

Biological Products, (No Diagnostic Substances)

Cardiol Therapeutics Inc. is a Canadian life sciences company focused on the development of pharmaceutical therapies and therapeutic strategies. Its primary activities center on the research, preclinical evaluation, and clinical study of novel drug candidates designed to address inflammation, cardiac disorders, and related cardiovascular conditions. Rather than distributing mass-market consumer products or operating commercial retail segments, the entity concentrates its operations entirely on biotechnology and biopharmaceutical research programs aimed at clinical validation for patient populations suffering from heart diseases.

Company profile, executives and history

Cardiol Therapeutics stock: common questions

What is Cardiol Therapeutics's stock price?

CRDL closed at $0.86 on Nov 20, 2026, down 2.28% on the day.

What is Cardiol Therapeutics's market cap?

Cardiol Therapeutics was worth $86.48M at the close on Nov 20, 2026: the share price times the diluted shares outstanding.

What is CRDL's P/E ratio?

Cardiol Therapeutics lost money over fiscal 2025 (diluted EPS -0.39 CAD), so it has no meaningful P/E ratio.

Does Cardiol Therapeutics pay a dividend?

No. Cardiol Therapeutics has not paid a cash dividend over the last twelve months.

How has CRDL stock performed over the past year?

Including dividends, CRDL returned -10.6% over the past year, against +6.9% for the S&P 500.

Who are Cardiol Therapeutics's competitors?

Companies most similar to Cardiol Therapeutics by business, industry and size include RLAY, CLDI, SLDB, PALI, ENGN.

See a number that looks wrong?